A Multimodality Video-Based AI Biomarker For Aortic Stenosis Development And Progression

Evangelos K. Oikonomou MD DPhil[a], Gregory Holste BA[a,b], Neal Yuan MD[c,d], Andreas Coppi PhD[e], Robert L. McNamara MD MHS[a], Norrisa Haynes MD MPH,[a] Amit N. Vora MD MPH[a], Eric J. Velazquez MD[a], Fan Li PhD[f,g], Venu Menon MD[h], Samir R. Kapadia MD FACC FAHA[h], Thomas M Gill MD[i], Girish N. Nadkarni MD MPH[j,k], Harlan M. Krumholz MD SM[a,e], Zhangyang Wang PhD[b], David Ouyang MD[l,m], Rohan Khera MD MS[a,e,n,o,p*]

[a] Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA

[b] Department of Electrical and Computer Engineering, The University of Texas at Austin, Austin, TX, USA

[c] Department of Medicine, University of California San Francisco, San Francisco, CA, USA

[d] Division of Cardiology, San Francisco Veterans Affairs Medical Center, San Francisco, CA, USA

[e] Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, CT, USA

[f] Department of Biostatistics, Yale School of Public Health, New Haven, CT, USA

[g] Center for Methods in Implementation and Prevention Science, Yale School of Public Health, New Haven, CT, USA

[h] Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.

[i] Section of Geriatrics, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.

[j] The Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA

[k] Division of Nephrology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA

[l] Department of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA

[m] Division of Artificial Intelligence in Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA

[n] Section of Biomedical Informatics and Data Science, Yale School of Medicine, New Haven, CT

[o] Section of Health Informatics, Department of Biostatistics, Yale School of Public Health, New Haven, CT

[p] Associate Editor, JAMA

Article type: Original investigation

Total word count for text only: 3,672 words

Figures: 3; **Tables:** 2

*Address for correspondence:

Rohan Khera, MD, MS

195 Church St, 6th Floor, New Haven, CT 06510

203-764-5885; rohan.khera@yale.edu; @rohan_khera

ABSTRACT

Importance: Aortic stenosis (AS) is a major public health challenge with a growing therapeutic landscape, but current biomarkers do not inform personalized screening and follow-up.

Objective: A video-based artificial intelligence (AI) biomarker (Digital AS Severity index [DASSi]) can detect severe AS using single-view long-axis echocardiography without Doppler. Here, we deploy DASSi to patients with no or mild/moderate AS at baseline to identify AS development and progression.

Design, Setting, and Participants: We defined two cohorts of patients without severe AS undergoing echocardiography in the Yale-New Haven Health System (YNHHS) (2015-2021, 4.1[IQR:2.4-5.4] follow-up years) and Cedars-Sinai Medical Center (CSMC) (2018-2019, 3.4[IQR:2.8-3.9] follow-up years). We further developed a novel computational pipeline for the cross-modality translation of DASSi into cardiac magnetic resonance (CMR) imaging in the UK Biobank (2.5[IQR:1.6-3.9] follow-up years). Analyses were performed between August 2023-February 2024.

Exposure: DASSi (range: 0-1) derived from AI applied to echocardiography and CMR videos.

Main Outcomes and Measures: Annualized change in peak aortic valve velocity (AV-V_{max}) and late (>6 months) aortic valve replacement (AVR).

Results: A total of 12,599 participants were included in the echocardiographic study (YNHHS: *n*=8,798, median age of 71 [IQR (interquartile range):60-80] years, 4250 [48.3%] women, and CSMC: *n*=3,801, 67 [IQR:54-78] years, 1685 [44.3%] women). Higher baseline DASSi was associated with faster progression in AV-V_{max} (per 0.1 DASSi increments: YNHHS: +0.033 m/s/year [95%CI:0.028-0.038], n=5,483, and CSMC: +0.082 m/s/year [0.053-0.111], n=1,292), with levels ≥ vs <0.2 linked to a 4-to-5-fold higher AVR risk (715 events in YNHHS; adj.HR 4.97 [95%CI: 2.71-5.82], 56 events in CSMC: 4.04 [0.92-17.7]), independent of age, sex, ethnicity/race, ejection fraction and AV-V_{max}. This was reproduced across 45,474 participants (median age 65 [IQR:59-71] years, 23,559 [51.8%] women) undergoing CMR in the UK Biobank (adj.HR 11.4 [95%CI:2.56-50.60] for DASSi ≥vs<0.2). Saliency maps and phenome-wide association studies supported links with traditional cardiovascular risk factors and diastolic dysfunction.

Conclusions and Relevance: In this cohort study of patients without severe AS undergoing echocardiography or CMR imaging, a new AI-based video biomarker is independently

associated with AS development and progression, enabling opportunistic risk stratification across cardiovascular imaging modalities as well as potential application on handheld devices.

KEYWORDS: artificial intelligence, imaging, aortic stenosis, risk stratification, computer vision

INTRODUCTION

With the expanding availability of transcatheter and surgical aortic valve replacement (AVR) procedures that effectively modify the prognosis of aortic stenosis (AS),[1–4] there has been a focus on the timely identification of individuals at risk of rapid progression.[5–8] Such efforts have been limited by the high prevalence of aortic sclerosis, variable progression rates, [9–11] and marked heterogeneity in the condition and its drivers.[12–15] As monitoring continues to depend on referrals for comprehensive testing by Doppler echocardiography, there is an unmet need to develop more precise algorithms to better define the personalized trajectory of AS.

We recently developed a deep learning (DL) strategy that uses a self-supervised, contrastive learning approach to learn the computational representation of severe AS on simple parasternal long axis (PLAX) videos without Doppler,[16] a standard echocardiographic view easily captured on handheld devices.[16,17] The predicted model-derived phenotype score, the Digital AS Severity index (DASSi), demonstrated excellent performance (Area Under the Receiver Operating Characteristic curve [AUROC] of 0.94-0.98) for the discrimination of severe AS across 9,338 studies in three distinct cohorts.[16]

In the present study, we hypothesized that, as DASSi identifies the echocardiographic signature of severe AS, it may stratify the risk of AS development and progression among individuals without AS or with early valve sclerosis and stenosis, independent of traditional Doppler parameters. Furthermore, we hypothesized that the anatomical and temporal information learned by DASSi through self-supervised pre-training on a video-based modality[16] would generalize to other modalities where the cinematic representation of cardiac activity is captured. We examined this using data from two health system-based echocardiography cohorts across the U.S., as well as cardiac magnetic resonance (CMR) data from the UK Biobank[18] after developing a computational pipeline for cross-modal translation, thus spanning a range of geographical settings, imaging modalities, and phenotypes.

METHODS

Study Design, Study Population and Data Source:

Echocardiography Study: This was a multi-center retrospective cohort study of patients without severe AS (with moderate, mild, or no AS) who underwent clinical echocardiography and were followed longitudinally within their respective health systems (**Figure 1A).** Participants were

independently drawn from 5 hospitals affiliated with Yale-New Haven Health System (YNHHS) across Connecticut and Rhode Island between 2015-2021, and from Cedars-Sinai Medical Center (CSMC) (Los Angeles, California) between 2018-2019 to define two nested sub-cohorts within each center: (1) A *longitudinal echocardiography cohort* of individuals undergoing clinically-indicated transthoracic echocardiography (TTE) at two or more timepoints; and (2) a *clinical outcomes cohort* which included all individuals with longitudinal follow-up for AVR. Eligible individuals had i) baseline peak aortic valve velocity (AV-V_{max}) of <4 m/sec, ii) no prior AVR, and iii) PLAX videos available for processing. To avoid bias, none of the patients from the original training set were included.[16] Moreover, the YNHHS cohort was specifically enriched for cases of mild/moderate AS, whereas the CSMC cohort sampled cases at random, reflecting local AS prevalence (*Supplement*).

CMR study/UK Biobank: The UK Biobank represents a prospective observational study of 502,468 participants aged 40-69 years. We performed a post-hoc analysis on 45,474 individuals (182 [0.4%] patients with AS of undetermined severity by diagnosis codes) who enrolled in the CMR sub-study between 2014-2020,[18,19] after excluding individuals who had withdrawn consent, had prior AVR or videos that failed technical preprocessing (**Figure 1B**).

Across all three cohorts reporting stands consistent with the STROBE statement.[29] Race and ethnicity were self-reported by the participants. In the YNHHS cohort, race categories included African American, Asian, White, and other, which included American Indian or Alaskan Native, Native Hawaiian or Pacific Islander, more than one race, unknown, or not reported. Hispanic ethnicity was reported separately. In the CSMC cohort, Hispanic ethnicity was included as an additional field under race/ethnicity. In the UKB, race groups included Asian (or Asian British, or Chinese), Black (or Black British), White, and other, which included more than one race, unknown, or not reported.

Echocardiogram/CMR Interpretation: All clinical echocardiograms were reviewed by board-certified cardiologists in the local laboratories who determined the presence and severity of AS according to the American Society of Echocardiography.[9,20] Measurements other than DASSi were derived from the structured echocardiographic reports. The CMR studies in the UK Biobank were performed as part of a research protocol, with left ventricular ejection fraction (LVEF) measurements previously measured in an automated manner (*Supplement*).[21,22]

Cardiac magnetic resonance (CMR) pre-processing: To test the cross-modal generalizability of the video-based algorithm, we defined a novel pipeline that extracts individual CMR files, identifies long-axis cine views of the left ventricular outflow tract, and compiles these into cine videos. These are then rotated, cropped to cardiac outline, and inverted to grayscale to create clips that loosely mimic the acquisition of a PLAX view on echocardiography (*Supplement*).

DASSi calculation: DASSi can be directly quantified using a simple two-dimensional video.[16] Our algorithm provides a numerical probability of severe AS phenotype ranging from 0 (lowest probability) to 1 (highest probability). For reference, the validated cut-off for *screening of severe AS* in the general population was previously set at 0.607.[16] Deployment of DASSi involves sequential automated steps that include de-identification, down-sampling, automated view classification, and inference using an ensemble model (*Supplement*). We computed DASSi at the level of each echocardiographic study by averaging video-level predictions, as previously described.[16,23] For CMR, we applied DASSi directly to the pre-processed PLAX-like CMR videos (one video per patient).

Definition of outcomes:

Echocardiographic outcomes: The *primary echocardiographic outcome* was the annualized rate of change in the AV-V_{max} (m/sec/year). If three or more studies were present, we calculated the rate of change as the coefficient of a univariate ordinary least squares regression model of time against AV-V_{max}. To avoid outlier effects, we winsorized the rate of change to no less than -1 m/sec/year and no more than +2 m/sec/year.[24] We chose this over the aortic valve area (AVA) or mean gradient, as these were not consistently measured in patients without AS (missing in 36.8% and 29.0% of cases, respectively). *Secondary echocardiographic outcomes* were: i) progression to a higher severity (mild-moderate-severe) stage, ii) development of any (≥mild) AS (among patients without AS at baseline), iii) and a sensitivity analysis on discrimination of participants with fast (≥0.4 m/sec/year) vs no measured progression (*no increase*) in AV-V_{max}.

Clinical outcomes: The *primary clinical outcome* was time-to-AVR, with all-cause mortality as a competing risk. These outcomes were derived from the linked institutional electronic health records, which provided dates of relevant procedures and the date of death, including out-of-

hospital deaths. Across cohorts, we applied a blanking period of 6 months to avoid contamination of our results from echocardiograms performed during acute illness or from early AVR in the setting of possible AS misclassification. (see ***Supplement***).

Model explainability:

Saliency maps: To supplement our prior work in echocardiography,[16] we generated sample saliency maps for selected high DASSi cases using the self-supervised part of the ensemble model and Gradient-weighted Class Activation Mapping (Grad-CAM).[25] We present the pixelwise maximum along the temporal axis to capture the most salient regions. ***Phenome-wide association study (PheWAS):*** To explore the clinical correlates of DASSi we applied a computational approach that automatically maps ICD-10 codes to 1,572 unique phenomic concepts, adjusts estimates for relevant covariates (age and sex), applies Bonferroni correction, and visualizes the results using a Manhattan plot.[26,27]

Statistical Methods: Categorical variables are summarized as counts (valid percentages), and continuous variables as mean ± standard deviation, or median [25th-75th percentile], unless specified otherwise. Normally distributed continuous variables between two groups were compared by unpaired t-test. Pairwise comparisons between continuous variables or an ordinal and a continuous variable were performed using Spearman's ρ coefficient. Across all multivariable regression models covariates with missing values were imputed using non-parametric chained equation imputation with random forests by including all model covariates (age/sex/race/ethnicity/AV-V_{max}/DASSi/baseline LVEF).[28] Correlations between continuous variables were visualized using Loess regression plots that use local weighted regression to fit smooth curves.

For the analysis of the echocardiographic and clinical outcomes, we defined nested models that included the patient's age, sex, race, ethnicity, AV-V_{max}, and LVEF at baseline, followed by the addition of DASSi. For the rate of change in AV-V_{max}, we fit a multivariable generalized linear model (GLM) and compared the improvement in model performance when adding DASSi using the likelihood-ratio (LR) chi-squared test. Calibration was examined based on the alignment between observed progression rates across progressively higher DASSi in the CSMC cohort based on the YNHHS models. The performance of the two models in

discriminating individuals with fast vs no progression was examined by comparison of model AUROC by DeLong's test. Based on the clinical interaction between related AS metrics, we evaluated an interaction term between $AV\text{-}V_{max}$, or the dimensionless valve index (DVI), and DASSi and mapped the results using contour plots. We also present tables of sensitivity, specificity, positive (LR+) and negative LR (LR-) for $AV\text{-}V_{max}$ progression across $DASSi/AV\text{-}V_{max}$ groups.

For the composite outcome of time-to-AVR, time-to-next severity stage, or any AS, we first fit multivariable Cox regression models to account for the variable length of follow-up. The proportionality of hazards was assessed by visualizing Schoenfeld residuals. For the analysis of AVR with death as a competing risk, we fit multivariable Fine-Gray proportional sub-distribution hazard regression models. Using nested models that included baseline predictors with or without DASSi, we assessed the improvement in discrimination and reclassification with DASSi by a LR test, but also C-statistic, categorical net reclassification improvement (NRI) indices (defining low, intermediate and high-risk categories based on a risk of AVR of <5%, 5-20% and ≥20% at the median follow-up) and integrated discrimination improvement (IDI). The latter are only presented in the YNHHS cohort due to limited event counts in the CSMC or UKB cohorts (n=715, versus 56, and 52 events respectively). Calibration curves are presented at t=4 years (rounded median follow-up). We also present adjusted survival curves across DASSi groups, and forest plots for subgroup analyses. The association of the top PheWAS hits with DASSi was explored in age- and sex-adjusted multivariable linear regression models.

All statistical tests were two-sided with a significance level of 0.05 (except for the PheWAS analysis where a Bonferroni correction was applied). Where needed, 95% confidence intervals (CI) were derived from bootstrapping (200 replications). Analyses were performed using Python (version 3.11.2) and R (version 4.2.3).

Ethical Approval of Studies and Informed Consent: The study was reviewed by the Yale and Cedars-Sinai Institutional Review Boards (IRBs), which approved the study protocol and waived the need for informed consent as the study represents a secondary analysis of existing data (Yale IRB ID #2000029973). The UK Biobank analysis was conducted under research application #71033.

RESULTS

Study overview and population

The YNHHS echocardiography cohort consisted of 8,798 patients (4,250 [48.3%] women) with a median age of 71 [IQR:60-80] years. Patients self-identified with the following race categories: 737 (8.4%) African American, 108 (1.2%) Asian, 6,347 (72.1%) White, and 1,606 (18.3%) other. Moreover, 613 (7.0%) self-identified as Hispanic. At the time of the baseline echocardiographic assessment, 1,047 (11.9%) participants had aortic sclerosis without stenosis, 2,017 (22.9%) mild AS and 979 (11.1%) moderate AS.

The CSMC echocardiography cohort included 3,801 participants (1,685 [44.3%] women) with a median age of 67 [IQR:54-78] years. Patients self-identified with the following race and ethnicity categories: 551 (14.5%) African American, 296 (7.8%) Asian, 424 (11.2%) Hispanic, 2,152 (56.6%) White, and 378 (9.9%) other. At baseline, 3,392 (89.2%) had no AS, 251 (6.6%) sclerosis without stenosis, 83 (2.2%) mild AS, and 75 (2.0%) moderate AS.

From the UK Biobank, we included 45,474 individuals (65 [IQR:59-71] years, 23,559 [51.8%] women), 182 (0.4%) of whom had AS (**Table 1** and **eTable 1**). Patients self-identified with the following race categories: 619 (1.4%) Asian, 304 (0.7%) Black (or Black British), 43,990 (96.7%) White, and 561 (1.2%) other.

Baseline DASSi phenotyping on echocardiography

In the YNHHS cohort, the median DASSi was 0.24 [IQR:0.10-0.47]. Higher baseline DASSi was associated with greater AS severity by traditional Doppler-derived parameters (AV-V_{max}: ρ=0.63, [n=8,798]; mean AV gradient: ρ=0.64, [n=6,220]; AVA: ρ=-0.53, [n=5,410]; and DVI: ρ=-0.63, [n=8,163], all p<0.001). There was a modest correlation with diastolic dysfunction by E/e' (ρ=0.36, [n=7,079]), left atrial volume index (ρ=0.31, [n=7,421]), and right ventricular systolic pressure (ρ=0.18, [n=6,312], p<0.001 for all three). DASSi was independent of LVEF (ρ=-0.01, [n=8,608], p=0.39) and stroke volume (ρ=-0.02, [n=7,073], p=0.11). Collectively, these parameters explained less than half of the variation in DASSi (R^2=0.46, [95%CI:0.44-0.49]).

DASSi and echocardiographic progression of AS

YNHHS cohort: In total, 5,483 of 8,798 patients (62.3%) in the YNHHS cohort had at least one follow-up study (median 4 [IQR:2-5] studies/patient) within a median of 3.5 [IQR:2.3-4.6] years. DASSi ranged from 0.14 [IQR:0.05-0.27] among patients without AS or sclerosis to 0.61 [IQR:0.48-0.72] among patients with moderate AS (**eFigure 1A-B**).

When stratified by DASSi, the annual change in $AV-V_{max}$ ranged from 0.04 ± 0.01 (standard error of mean) m/sec/year for DASSi values <0.2 at baseline, to 0.21 ± 0.01 for baseline values ≥0.6 (**eFigure 2**), a trend that persisted within each distinct baseline AS stenosis group (**Figure 2A** and **eTable 2**). The addition of DASSi to a model consisting of baseline $AV-V_{max}$, LVEF, age, sex, and race/ethnicity was associated with an +0.033 m/s/year [95%CI:0.028-0.038, $p<0.001$] adjusted annualized $AV-V_{max}$ increase independent of the number of studies and follow-up length (**Figure 2B**) and significantly improved baseline model performance ($p<0.001$ by LR test). There was interaction between baseline DASSi and the flow-corrected DVI ($p=0.002$ for interaction), but not $AV-V_{max}$ ($p=0.26$ for interaction) (**Figure 2C-D**), with higher DASSi associated with faster progression rates for lower baseline DVI. The association between DASSi and $AV-V_{max}$ change remained consistent across demographic subgroups, impaired or preserved left ventricular function (LVEF $\geq$ vs <50%) and baseline $AV-V_{max}$ strata (**eFigure 3**).

DASSi improved the baseline model's ability to discriminate individuals with the fastest progression rates (≥0.4 m/sec/year, $n=693$) from those without progression ($n=1836$), with AUROC increasing from 0.63 to 0.70 (δ[AUROC]=0.07 [95%CI:0.05-0.09]). Among individuals with $AV-V_{max}<2.5$ m/sec, a DASSi of ≥0.5 was linked to LR(+) of 5.9 for identifying participants with $AV-V_{max}$ change ≥0.4 m/sec/year, while for $AV-V_{max}$ 3.0-3.9 m/sec a DASSi <0.2 was associated with LR(-) of 0.1 (**eTable 3**).

In total, 2,037 (37.2%) participants had a follow-up echocardiographic report describing a higher AS severity grade than their baseline study. Greater DASSi was associated with a higher adjusted risk of progressing to a higher severity stage (adj.HR 1.14 [95%CI: 1.12-1.17], $p<0.001$, per 0.1 DASSi increments) after multivariable adjustment including baseline AS severity. DASSi was also positively associated with the future development of *any* AS ($n=325$ new AS cases) in a subset of 2,091 patients without AS at baseline (per 0.1 incr.; adj.HR: 1.16 [95%CI:1.09-1.23], $p<0.001$).

These results were replicated in the geographically distinct CSMC cohort, where 1,292 patients had echocardiographic follow-up over a median of 1.1 [IQR:0.4-1.8] years. DASSi was

independently associated with the rate of change in AV-V_{max} (per 0.1 increments: adj. coefficient +0.08 m/s/year [95%CI:0.05-0.11], $p<0.001$; and $p<0.001$ by LR test compared to the baseline model). There was also significant improvement in discrimination of fast vs no progression (n=269 vs 634, respectively; AUROC 0.59 to 0.67; δ[AUROC]=0.08 [95%CI:0.04-0.11]). Higher baseline DASSi was also associated with a higher adjusted risk of progressing to a higher AS stage (*n*=183 cases, adj. HR 1.18 [95%CI:1.08-1.29], $p<0.001$), including progression to new AS (*n*=148 new cases of mild or greater AS among 1208 patients without stenosis at baseline; adj. HR 1.19 [95%CI:1.07-1.33], $p<0.001$), with overall alignment of observed and predicted rates across cohorts and DASSi thresholds (**eFigures 2 and 4**).

DASSi and future AVR

The 8,798 patients in the YNHHS cohort were followed for 4.1 [IQR:2.4-5.4] years. Following a blanking period of 6 months, 715 underwent AVR. Higher baseline DASSi was independently associated with a higher adjusted risk of AVR (per 0.1 increments; adj.HR 1.21 [95%CI:1.16-1.26], $p<0.001$) (**Table 2, eTable 4,** and **eFigure 5**). Compared with the reference group of DASSi<0.2, the risk of AVR increased from 2.9-fold higher for DASSi 0.2-0.4, to 4.7-fold and 5.4-fold higher for those with DASSi levels 0.4-0.6, and ≥0.6, respectively (**Table 2** and **eFigure 6A**). The prognostic value of DASSi was consistent across sex, age, LVEF, and AV-V_{max} strata (**eFigure 7**), and offered marginal improvements in reclassification and discrimination beyond baseline ($p<0.001$ by LR test; C-statistic 0.896 to 0.902 (δ[C-statistic]: 0.006 [95%CI:0.002-0.009]), categorical NRI 0.05 [95%CI:0.02-0.08], and IDI: 0.006 [95%CI: 0.003-0.009]).

In the CSMC cohort there were 56 AVR procedures performed (>6 months) among 3,801 individuals followed over a median of 3.4 [IQR:2.8-3.9] years. Similar to the YNHHS cohort, when compared with the reference group of DASSi<0.2, those with DASSi ≥0.2 had a 4-fold higher adjusted risk of undergoing AVR at CSMC, though 95% confidence intervals were wide and included the null value (adj.HR 4.04 [95%CI: 0.92-17.70], $p=0.06$) (**eFigure 6B; Table 2**). A YNHHS-based model incorporating age, sex, AV-V_{max}, and DASSi showed good calibration in the CSMC cohort with a mean absolute error of 0.6% for AVR at 4 years (**eFigure 8**), whereas the addition of DASSi to the baseline parameters improved the goodness-of-fit of the model ($p<0.001$ by LR test).

Cross-modal validation of DASSi using CMR videos: We designed a novel pipeline that enables direct cross-modal application of the original DASSi algorithm to cine CMR videos by creating pseudo-PLAX echo views. Activation maps across two examples with the highest DASSi (0.5 to 0.6) showed that the model focused on myocardial structures, such as the left atrium and right ventricle (**Figure 3A**). CMR-based DASSi successfully discriminated between patients with vs without diagnosed AS (DASSi: 0.32 [IQR:0.25-0.38], *n*=182, vs 0.19 [IQR:0.12-0.26], *n*=45,292, respectively, *p*<0.001) (**Figure 3B**).

Over 2.5 [IQR 1.6-3.9] years, there were 52 AVR procedures (>6 months). Compared with the reference group of <0.2, individuals with DASSi levels 0.2-0.4, and 0.4-0.6 had an 11- and 24-fold higher adjusted risk of AVR, independent of age, sex, race/ethnicity, history of AS, and baseline LVEF (**Figure 3C, Table 2**). There were no individuals with DASSi values of 0.6 or greater in this cohort.

Phenotypic correlates of DASSi: In age- and sex-adjusted PheWAS analyses, DASSi was associated with cardiovascular-specific risk factors – hypertension, atrial fibrillation, obesity, diabetes mellitus, and hypercholesterolemia (**eFigure 9**). Age and sex explained 19% of the variation in DASSi, whereas the addition of the top 10 hits only increased this to 21% (R^2=0.21). Further adjustment for these phenotypes did not impact the prognostic value of DASSi for AVR (adj.HR 2.12 [95%CI:1.50-2.99], *p*<0.001).

DISCUSSION

In this multinational cohort study of 58,073 individuals with no or early AS, a novel video-based biomarker of AS – DASSi – was reproducibly associated with the future risk of AS development and progression independent of key clinical parameters and baseline severity by Doppler. The prognostic association of DASSi was shown across three geographically, temporally, and phenotypically distinct cohorts, including patients undergoing clinical echocardiography, the original modality used for its training, as well as a prospective cohort of protocolized CMR imaging in the UK Biobank. These findings support the use of DASSi, a cross-modal AI biomarker for both opportunistic AS screening on echocardiography as well as deeper phenotyping of AS on standard non-invasive modalities and potentially handheld devices.

Efforts to identify individuals at risk of AS progression have been limited by the large burden of milder forms of aortic valve disease, such as aortic sclerosis, found in ~26% of individuals over 65 years.[11,30,31] However, a challenge in personalizing patient follow-up is the marked variability in the progression rates of patients within similar Doppler-adjudicated severity stages.[32–35] Traditional risk factors such as hypercholesterolemia, smoking, renal dysfunction, and elevated natriuretic peptides, lack specificity for AS,[15,36] while alternative Doppler-derived indices require skilled acquisition and modifications to the scanning protocols.[36,37]

Deep learning-enhanced, two-dimensional echocardiography with DASSi aims to bridge this gap by providing a Doppler-independent AS severity metric that can be computed from any portable or standard echocardiogram. Trained to detect generalizable features associated with the severe AS phenotype,[16] DASSi maintains its prognostic value across the spectrum of AS stages, identifying individuals who do not meet traditional criteria for severe AS, yet exhibit fast rates of progression. Critically, DASSi has several features that make it generalizable and scalable. Unlike prior methods that have utilized structured echo reports and measurements,[37–40] Doppler images,[41] or still images of the aortic valve,[42] DASSi can be directly applied to unprocessed, standard PLAX videos, without the need for any Doppler or two-dimensional measurements, and provides a reader-independent metric to supplement an echocardiographer's impression, assisting in standardized severity classification.[16] Furthermore, DASSi can be applied to videos obtained at the point-of-care by individuals with minimal to no training.[16,17] The value of this approach is supported by consistent and robust effect sizes for both intermediate echocardiographic and long-term clinical outcomes, reproduced across multinational cohorts undergoing both clinically indicated and protocolized imaging.

The cross-modality validation is included not merely to suggest a role for CMR in opportunistic AS screening, but because it shows that DASSi flags a distinct myocardial and valvular phenotypic signature rather than modality- or population-specific confounders.[43] The specificity of the algorithm is further illustrated by representative saliency maps and PheWAS, suggesting cardiovascular-specific associations with traditional risk factors and links to extra-valvular phenotypes of myocardial remodeling and diastolic dysfunction that may flag AS progression.[44] However, these only partially explain the variability in DASSi, highlighting the

need for multiparametric phenotyping. This innovative framework also suggests a generalizable way to test the validity of new AI-derived echocardiographic biomarkers.

Certain limitations merit consideration. In the echocardiography study, repeat imaging was clinically determined rather than based on a study protocol, thus favoring patients with higher symptom burden and closer interaction with the healthcare system. Reassuringly, our analyses revealed consistent results across varying levels of AS severity at baseline, independent of the frequency of echocardiographic follow-up, for both echocardiographic and clinical outcomes, with the overall findings reproduced in the prospectively enrolled population of the UK Biobank. Further prospective clinical studies will explore the longitudinal association between DASSi and its changes with AS progression across protocol-defined echocardiographic intervals and using multi-modality calibration in racially and ethnically diverse cohorts. Second, it is possible that DASSi flags a cardiovascular phenotype that is not exclusive to AS, a condition that shares several risk factors with coronary artery disease, stroke, and heart failure;[45] however, analyses across distinct cohorts and outcomes suggest a consistent association with AS-specific outcome measures. Third, outcome ascertainment is the hospital-based echocardiography cohorts was performed through local electronic health records. Thus, events that occurred in different hospitals, or deferral of AVR due to patient preference or ineligibility may not be adequately captured. Indeed, estimates of incremental discrimination and risk stratification were limited by low event counts in two of the three cohorts given the predominance of patience without AS at baseline. Finally, we focused on AV-V$_{max}$, given its more complete capture in our dataset. Though this parameter may be flow-dependent, we demonstrate that associations persisted despite adjusting for LVEF, when modeling against the DVI, and when assessed against future clinical events.

CONCLUSION

Our study defines a novel AI-based videographic phenotyping of cardiac anatomy and function to detect distinct clinical trajectories among patients with no or non-severe AS, which generalize across multi-national cohorts and non-invasive modalities. By practical deployment in any setting where video-based cardiac imaging is obtained, DASSi may enable more precise risk stratification for the most common valvular disorder without any changes in the image acquisition protocols.

ARTICLE INFORMATION

Conflict of interest disclosures: R.K. is an Associate Editor of JAMA and receives research support, through Yale, from the Blavatnik Foundation, Bristol-Myers Squibb, Novo Nordisk, and BridgeBio. He is a coinventor of U.S. Provisional Patent Applications 63/177,117, 63/428,569, 63/346,610, 63/484,426, and 63/508,315, and a co-founder of Ensight-AI, Inc. (all outside the current work). R.K. and E.K.O. are co-founders of Evidence2Health, a health analytics company. E.K.O. is a co-inventor in patent applications (US17/720,068, 63/619,241, 63/177,117, 63/580,137, 63/606,203, 63/619,241, WO2018078395A1, WO2020058713A1), has been an ad hoc consultant for Caristo Diagnostics Ltd, and has received royalty fees from technology licensed through the University of Oxford. H.M.K. works under contract with the Centers for Medicare & Medicaid Services to support quality measurement programs, was a recipient of a research grant from Johnson & Johnson, through Yale University, to support clinical trial data sharing; was a recipient of a research agreement, through Yale University, from the Shenzhen Center for Health Information for work to advance intelligent disease prevention and health promotion; collaborates with the National Center for Cardiovascular Diseases in Beijing; receives payment from the Arnold & Porter Law Firm for work related to the Sanofi clopidogrel litigation, from the Martin Baughman Law Firm for work related to the Cook Celect IVC filter litigation, and from the Siegfried and Jensen Law Firm for work related to Vioxx litigation; chairs a Cardiac Scientific Advisory Board for UnitedHealth; was a member of the IBM Watson Health Life Sciences Board; is a member of the Advisory Board for Element Science, the Advisory Board for Facebook, and the Physician Advisory Board for Aetna; and is the co-founder of Hugo Health, a personal health information platform, and co-founder of Refactor Health, a healthcare AI-augmented data management company, and Ensight-AI, Inc. All other authors declare no competing interests.

Funding: This study was supported by grants 1F32HL170592-01 (EKO) and K23HL153775 (RK) from the National Heart, Lung, and Blood Institute of the National Institutes of Health and award 2022060 (RK) from the Doris Duke Charitable Foundation. TMG is supported by P30AG021342. The funders had no role in the design and conduct of the study; collection,

management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Access to Data and Data Analysis: EKO and RK had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Data sharing agreement: The UK Biobank structured and imaging data are publicly available for research use (https://www.ukbiobank.ac.uk/enable-your-research/apply-for-access) following an approved access application. The raw clinical echocardiograms from Yale-New Haven Health and Cedars-Sinai Medical Center cannot be made publicly available since they contain personal identifiable information. The code for the analysis can be made available upon reasonable request.

TABLES

Table 1. Table of cohort demographics.

Feature	Description	Echocardiography		CMR
		YNHHS	**CSMC**	**UK Biobank**
Total participants		**8,798**	**3,801**	**45,474**
Age (years)		71 [60, 80]	67 [54, 78]	65 [59-71]
Sex	Female	4,250 (48.3)	1,685 (44.3)	23,559 (51.8)
	Male	4,548 (51.7)	2,116 (55.7)	21,915 (48.2)
Race	*African American/Black*	737 (8.4)	551 (14.5)	-
	Asian	108 (1.2)	296 (7.8)	619 (1.4)
	Black (or Black British)	-	-	304 (0.7)
	White	6,347 (72.1)	2,152 (56.6)	43,990 (96.7)
	Other [a]	1,606 (18.3)	378 (9.9)	561 (1.2)
Ethnicity	*Hispanic* [b]	613 (7.0)	424 (11.2)	-
LVEF (%)		62 [57,66]	61 [54, 66]	58 [54-61]
Aortic Stenosis (AS)	*None reported*	4,755 (54.1)	3,392 (89.2)	182 (0.4)[c]
	Sclerosis	1,047 (11.9)	251 (6.6)	
	Mild	2,017 (22.9)	83 (2.2)	
	Moderate	979 (11.1)	75 (2.0)	
AV area (cm^2)		1.5 [1.2, 1.9]	2.0 [1.3, 2.6]	-
AV mean gradient (mm Hg)		11.5 [5.3, 17.3]	5.0 [3.0, 11.0]	-
AV peak velocity (m/s)		1.8 [1.4, 2.6]	1.4 [1.1, 1.8]	-
DASSi		0.24 [0.10, 0.47]	0.15 [0.07, 0.30]	0.24 [0.10, 0.47]
Total follow-up (years)		4.1 [2.4-5.4]	3.4 [2.8-3.9]	2.5 [1.6-3.9]
Death rate (≥6 months)	*(Per 100 participant years)*	4.1 (n=1,284)	6.1 (n=644)	0.3 (n=358)
AVR rate (≥6 months)	*(Per 100 participant years)*	2.3 (n=715)	0.5 (n=56)	0.04 (n=52)

[a] Other race includes American Indian or Alaskan Native, Native Hawaiian or other Pacific Islander, more than one race, unknown, or not reported.
[b] Reported separately of race in the YNHHS cohort; reported with race in the CSMC cohort.
[c] AS was adjudicated by diagnosis codes in the UK Biobank. Severity is undetermined.
Categorical variables are summarized as counts (valid percentages after excluding missing values). Continuous variables are presented as median [25th, 75th percentile].
Abbreviations: AS: aortic stenosis; AV: aortic valve; AVR: aortic valve replacement; CMR: cardiac magnetic resonance; CSMC: Cedars-Sinai Medical Center; DASSi: digital aortic stenosis severity index; LVEF: left ventricular ejection fraction; YNHHS: Yale-New Haven Health System.

Table 2. Adjusted Cox regression estimates for DASSi and late AVR incidence.

DASSi	Outcome: AVR[a] HR [95% CI], *p* value (total counts)		
	Echocardiography		**CMR**
	YNHHS cohort (*n*=8,798; 715 events)[b]	**CSMC cohort** (*n*=3,801; 56 events)[b]	**UK Biobank cohort** (*n*=45,474; 52 events)[c]
Continuous DASSi per 0.1 increments	1.21 [1.16-1.26], *p*<0.001	1.08 [0.92-1.26], *p*=0.36	2.09 [1.54-2.83], *p*<0.001
DASSi groups			
Less than 0.2	Reference (*n*=3,837)	Reference (*n*=2,302)	Reference (*n*=24,579)
0.2 or greater	4.97 [2.71-.582], *p*<0.001 (*n*=4,961)	4.04 [0.92-17.70], *p*=0.06 (*n*=1,499)	11.4 [2.56-50.6], *p*=0.001 (*n*=20,895)
0.2 to less than 0.4	2.86 [1.90-4.30], *p*<0.001 (*n*=2,188)	3.67 [0.79-17.1], *p*=0.10 (*n*=881)	10.7 [2.36-48.8], *p*=0.002 (*n*=19,787)
0.4 to less than 0.6	4.67 [3.12-6.97], *p*<0.001 (*n*=1,601)	4.68 [1.00-21.87], *p*=0.05 (*n*=375)	24.3[4.64-120.7], *p*<0.001 (*n*=1,108)
0.6 or greater	5.38 [3.54-8.15], *p*<0.001 (*n*=1,172)	3.74 [0.76-18.35], *p*=0.10 (n=243)	n/a (*n*=0)

[a] Estimates for AVR were derived from Fine-Gray proportional sub-distribution hazards regression models with death as competing risk.
[b] adjusted for baseline age, left ventricular ejection fraction, peak aortic valve velocity, sex, race/ethnicity.
[c] adjusted for baseline age, left ventricular ejection fraction, aortic stenosis presence, sex, and race/ethnicity.
All events were recorded at least 6 months after the index imaging visit (following a 6-month blanking period).
AVR: aortic valve replacement; CI: confidence interval; CMR: cardiac magnetic resonance imaging; CSMC: Cedars-Sinai Medical Center;
DASSi: digital aortic stenosis severity index; HR: hazard ratio; YNHHS: Yale-New Haven Health System.

Figure Legends

A: Association between DASSi and AS development/progression on 2D-echo

B: Cross-modal validation of DASSi on CMR imaging

Figure 1 | Study design. AV-V_{max}: peak aortic valve velocity; AVR: aortic valve replacement; CMR: cardiac magnetic resonance; DASSi: digital aortic stenosis severity index; PLAX: parasternal long axis view.

Figure 2 | Stratifying the rate of aortic stenosis (AS) progression by DASSi. (A) Observed progression rates across DASSi subgroups stratified by baseline severity of AS (error bars denote the standard error of mean) in the YNHHS cohort. The counts of unique observations for each group are provided above each bar. **(B)** Loess regression curves with 95% confidence bands showing the association between baseline DASSi and the annual rate of change in the peak aortic valve velocity (AV-V_{max}), adjusted for baseline AV-V_{max}, left ventricular ejection fraction, age,

sex, ethnicity/race. **(C-D)** Contour plots examining the interaction between DASSi and **(C)** the baseline AV-V$_{max}$, as well as **(D)** the dimensionless valve index (DVI). On these plots, each dot represents a unique observation (participant); the horizontal/vertical axes represent the baseline DASSI/AV-V$_{max}$ values, respectively, and the colored contours denote the adjusted AV-V$_{max}$ progression rates. *AS: aortic stenosis; AV-V$_{max}$: peak aortic valve velocity; DASSi: digital aortic stenosis severity index; YNHHS: Yale-New Haven Health System.*

Figure 3 | Cross-modal evaluation of DASSi in the UK Biobank. (A) We designed a new computational pipeline that enabled the direct transformation of long-axis cine cardiac magnetic resonance (CMR) clips into PLAX-like cine videos. Saliency maps of individuals with the highest DASSi values (0.5-0.59) on CMR demonstrated that the DASSi algorithm focused on key cardiac structures, such as the left atrium and right ventricle. **(B)** Density plot of DASSi (probability that DASSi takes a given value among patients with AS and no AS undergoing CMR imaging in the UK Biobank). **(C)** Flexible adjusted hazard ratio curve for AVR or all-cause mortality based on a multivariable Cox regression model that included DASSi adjusted for age, sex, ethnic background, known AS and baseline left ventricular ejection fraction. *AS: aortic stenosis; AVR: aortic valve replacement; CI: confidence interval; CMR: cardiac magnetic resonance; DASSi: digital aortic stenosis severity index; HR: hazard ratio.*

REFERENCES

1. Eugène Marc, Duchnowski Piotr, Prendergast Bernard, et al. Contemporary Management of Severe Symptomatic Aortic Stenosis. *J Am Coll Cardiol*. 2021;78(22):2131-2143.

2. Otto CM, Prendergast B. Aortic-valve stenosis--from patients at risk to severe valve obstruction. *N Engl J Med*. 2014;371(8):744-756.

3. Kapadia SR, Leon MB, Makkar RR, et al. 5-year outcomes of transcatheter aortic valve replacement compared with standard treatment for patients with inoperable aortic stenosis (PARTNER 1): a randomised controlled trial. *Lancet*. 2015;385(9986):2485-2491.

4. Mack MJ, Leon MB, Thourani VH, et al. Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients. *N Engl J Med*. 2019;380(18):1695-1705.

5. Reardon MJ, Van Mieghem NM, Popma JJ, et al. Surgical or Transcatheter Aortic-Valve Replacement in Intermediate-Risk Patients. *N Engl J Med*. 2017;376(14):1321-1331.

6. Kang DH, Park SJ, Lee SA, et al. Early Surgery or Conservative Care for Asymptomatic Aortic Stenosis. *N Engl J Med*. 2020;382(2):111-119.

7. The Early Valve Replacement in Severe Asymptomatic Aortic Stenosis Study. Accessed June 2, 2022. https://clinicaltrials.gov/ct2/show/NCT04204915

8. Banovic M, Putnik S, Penicka M, et al. Aortic Valve Replacement Versus Conservative Treatment in Asymptomatic Severe Aortic Stenosis: The AVATAR Trial. *Circulation*. 2022;145(9):648-658.

9. Mitchell C, Rahko PS, Blauwet LA, et al. Guidelines for performing a comprehensive transthoracic echocardiographic examination in adults: Recommendations from the American society of echocardiography. *J Am Soc Echocardiogr*. 2019;32(1):1-64.

10. Delgado V, Clavel MA, Hahn RT, et al. How Do We Reconcile Echocardiography, Computed Tomography, and Hybrid Imaging in Assessing Discordant Grading of Aortic Stenosis Severity? *JACC Cardiovasc Imaging*. 2019;12(2):267-282.

11. Otto CM, Lind BK, Kitzman DW, Gersh BJ, Siscovick DS. Association of aortic-valve sclerosis with cardiovascular mortality and morbidity in the elderly. *N Engl J Med*. 1999;341(3):142-147.

12. Puls M, Beuthner BE, Topci R, et al. Impact of myocardial fibrosis on left ventricular remodelling, recovery, and outcome after transcatheter aortic valve implantation in different haemodynamic subtypes of severe aortic stenosis. *Eur Heart J*. 2020;41(20):1903-1914.

13. Gjertsson P, Caidahl K, Odén A, Bech-Hanssen O. Diagnostic and referral delay in patients with aortic stenosis is common and negatively affects outcome. *Scand Cardiovasc J*. 2007;41(1):12-18.

14. Willner Nadav, Prosperi-Porta Graeme, Lau Lawrence, et al. Aortic Stenosis Progression. *JACC Cardiovasc Imaging*. 2023;16(3):314-328.

15. Palta S, Pai AM, Gill KS, Pai RG. New insights into the progression of aortic stenosis: implications for secondary prevention. *Circulation*. 2000;101(21):2497-2502.

16. Holste G, Oikonomou EK, Mortazavi BJ, et al. Severe aortic stenosis detection by deep learning applied to echocardiography. *Eur Heart J*. Published online August 23, 2023. doi:10.1093/eurheartj/ehad456

17. Narang A, Bae R, Hong H, et al. Utility of a Deep-Learning Algorithm to Guide Novices to Acquire Echocardiograms for Limited Diagnostic Use. *JAMA Cardiol*. 2021;6(6):624-632.

18. Petersen SE, Matthews PM, Francis JM, et al. UK Biobank's cardiovascular magnetic resonance protocol. *J Cardiovasc Magn Reson*. 2016;18(1):1-7.

19. Sudlow C, Gallacher J, Allen N, et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. *PLoS Med*. 2015;12(3):e1001779.

20. Baumgartner H, Hung J, Bermejo J, et al. Echocardiographic assessment of valve stenosis: EAE/ASE recommendations for clinical practice. *J Am Soc Echocardiogr*. 2009;22(1):1-23; quiz 101-102.

21. Suinesiaputra A, Sanghvi MM, Aung N, et al. Fully-automated left ventricular mass and volume MRI analysis in the UK Biobank population cohort: evaluation of initial results. *Int J Cardiovasc Imaging*. 2018;34(2):281-291.

22. Bai W, Suzuki H, Huang J, et al. A population-based phenome-wide association study of cardiac and aortic structure and function. *Nat Med*. 2020;26(10):1654-1662.

23. Holste G, Oikonomou EK, Mortazavi B, Wang Z, Khera R. Self-supervised learning of echocardiogram videos enables data-efficient clinical diagnosis. *arXiv [csCV]*. Published online July 23, 2022. http://arxiv.org/abs/2207.11581

24. Nayeri A, Xu M, Farber-Eger E, et al. Initial changes in peak aortic jet velocity and mean gradient predict progression to severe aortic stenosis. *Int J Cardiol Heart Vasc*. 2020;30:100592.

25. Selvaraju RR, Cogswell M, Das A, Vedantam R, Parikh D, Batra D. Grad-CAM: Visual Explanations from Deep Networks via Gradient-based Localization. *arXiv [csCV]*. Published online October 7, 2016. http://arxiv.org/abs/1610.02391

26. Denny JC, Ritchie MD, Basford MA, et al. PheWAS: demonstrating the feasibility of a phenome-wide scan to discover gene-disease associations. *Bioinformatics*. 2010;26(9):1205-1210.

27. *PheWAS: The PheWAS R Package*. Github Accessed October 4, 2023. https://github.com/PheWAS/PheWAS

28. Stekhoven DJ, Bühlmann P. MissForest--non-parametric missing value imputation for mixed-type data. *Bioinformatics*. 2012;28(1):112-118.

29. von Elm E, Altman DG, Egger M, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *BMJ*. 2007;335(7624):806-808.

30. Otto CM. Aortic stenosis: even mild disease is significant. *Eur Heart J*. 2004;25(3):185-187.

31. Rosenhek R, Klaar U, Schemper M, et al. Mild and moderate aortic stenosis. Natural history and risk stratification by echocardiography. *Eur Heart J*. 2004;25(3):199-205.

32. Coisne A, Montaigne D, Aghezzaf S, et al. Association of Mortality With Aortic Stenosis Severity in Outpatients: Results From the VALVENOR Study. *JAMA Cardiol*. 2021;6(12):1424-1431.

33. Otto CM, Burwash IG, Legget ME, et al. Prospective study of asymptomatic valvular aortic stenosis. Clinical, echocardiographic, and exercise predictors of outcome. *Circulation*. 1997;95(9):2262-2270.

34. Hariri Essa H., El Halabi Jessica, Kassis Nicholas, et al. Sex Differences in the Progression and Long-Term Outcomes of Native Mild to Moderate Aortic Stenosis. *JACC Cardiovasc Imaging*. 0(0). doi:10.1016/j.jcmg.2023.06.006

35. Kebed K, Sun D, Addetia K, Mor-Avi V, Markuzon N, Lang RM. Progression of aortic stenosis and echocardiographic criteria for its severity. *Eur Heart J Cardiovasc Imaging*. 2020;21(7):737-743.

36. Howard T, Majmundar M, Sarin S, et al. Predictors of Major Adverse Cardiovascular Events in Patients With Moderate Aortic Stenosis: Implications for Aortic Valve Replacement. *Circ Cardiovasc Imaging*. 2023;16(7):557-565.

37. Seo JH, Kim KH, Chun KJ, Lee BK, Cho BR, Ryu DR. How can progression be predicted in patients with mild to moderate aortic valve stenosis? *Eur Heart J Cardiovasc Imaging*. Published online May 9, 2023. doi:10.1093/ehjci/jead099

38. Moualla SK, McCarthy PM, Thomas JD, et al. Artificial intelligence-enabled predictive model of progression from moderate to severe aortic stenosis. *Intelligence-Based Medicine*. 2022;6:100062.

39. Strange G, Stewart S, Watts A, Playford D. Enhanced detection of severe aortic stenosis via artificial intelligence: a clinical cohort study. *Open Heart*. 2023;10(2). doi:10.1136/openhrt-2023-002265

40. Sánchez-Puente A, Dorado-Díaz PI, Sampedro-Gómez J, et al. Machine Learning to Optimize the Echocardiographic Follow-Up of Aortic Stenosis. *JACC Cardiovasc Imaging*. 2023;16(6):733-744.

41. Krishna H, Desai K, Slostad B, et al. Fully Automated Artificial Intelligence Assessment of Aortic Stenosis by Echocardiography. *J Am Soc Echocardiogr*. 2023;36(7):769-777.

42. Wessler BS, Huang Z, Long GM Jr, et al. Automated Detection of Aortic Stenosis Using Machine Learning. *J Am Soc Echocardiogr*. 2023;36(4):411-420.

43. Bohbot Y, Renard C, Manrique A, et al. Usefulness of Cardiac Magnetic Resonance Imaging in Aortic Stenosis. *Circ Cardiovasc Imaging*. 2020;13(5):e010356.

44. Kampaktsis PN, Kokkinidis DG, Wong SC, Vavuranakis M, Skubas NJ, Devereux RB. The role and clinical implications of diastolic dysfunction in aortic stenosis. *Heart*. 2017;103(19):1481-1487.

45. Yan AT, Koh M, Chan KK, et al. Association Between Cardiovascular Risk Factors and Aortic Stenosis: The CANHEART Aortic Stenosis Study. *J Am Coll Cardiol*. 2017;69(12):1523-1532.